Aim This cross-sectional study of a group of women with abnormal cytology and high-risk human papillomavirus (hrHPV) infection compared genotyping HPV DNA and mRNA assays according to two age categories of women (S1: ≤30 and S2: >30 years). Methods The hrHPV DNA positive results of 105 cervical samples of women were pooled and those harbouring HPV-16, 18, 31, 33 and/or 45 DNA were tested for the type specific HPV oncogene E6/E7 overexpression (mRNA). Results Although HPV DNA testing showed a higher proportion of women infected by any of five hrHPVs in S1 group, total agreement of hrHPV DNA and mRNA positive results was higher in S2 group of women (75.8% v. 83.9%). The most prevalent type in both age groups was HPV-16. A 100% agreement of positivity of both tests was noted for HPV-18 and 33 in S1 group, and for HPV-18 in S2 group. Increasing concordance of HPV-16 and 31 DNA and mRNA positive results with the severity of cervical cytology was observed in S1 group of women. Absolute matching (100.0%) of positivity of both diagnostic tests was recorded in S2 ASCUS group (for HPV-16, 18 and 33), in S1 HSIL (for HPV-16, 18, 31 and 33), in S1 LSIL category (for HPV-18 and 33) and in S2 HSIL group (for HPV-18). Conclusion The results indicate the possibility of predicting the risk of persistent infection only by HPV DNA typing test, with no need for additional RNA testing in categories of infected women showing a high (absolute) agreement of positivity of both tests.
Changes to the National Cervical Screening Program (NCSP) for Healthcare providers From. 1AD;
2.
Khan M, Castle P, Lorincz A, Wacholder S, Sherman M, Scott D, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;1072–9.
3.
Castle P, Solomon D, Schiffman M, Wheeler C. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005;1066–71.
4.
Nygard M, Roysland K, Campbell S, Dillner J. Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme. BMJ Open. 2014;3460.
5.
Verdoodt F, Szarewski A, Halfon P, Cuschieri K, Arbyn M. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol. 2013;675–87.
6.
Cuschieri K, Whitley M, Cubie H. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol. 2004;65–70.
7.
Lu WJF, Wang D, Johnson Y, Johanning M, G. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer. 2002;2199–210.
8.
Doorbar J, Banks Q, Bravo L, Stoler I, Broker M, Stanley T, et al. The biology and life cycle of human papillomaviruses. Vaccine. 2012;55–70.
9.
Bulkmans N, Berkhof J, Bulk S, Bleeker M, Van Kemenade F, Rozendaal L, et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer. 2007;1419–24.
10.
Bulkmans N, Rozendaal L, Voorhorst F, Boeke A, Snijders P, Meijer C. POBASCAM, a population-based randomised controlled trial for implementation of high-risk HPV testing in cervical screening. Int J Cancer. 2004;94–101.
11.
Insinga R, Liaw K, Johnson L, Madeleine M. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2008;1611–22.
12.
Smith J, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and highgrade cervical lesions: a meta-analysis update. Int J Cancer. 2007;621–32.
13.
Us Preventive S, Task Force, Curry S, Krist A, Owens D, Barry M, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;674–86.
14.
Salimovic-Bešic I, Hukic M. Potential coverage of circulating HPV types by current and developing vaccines in a group of women in Bosnia and Herzegovina with abnormal Pap smears. Epidemiol Infect. 2015;2604–12.
15.
Salimović-Bešić I, Tomić-Čiča A, Smailji A, Hukić M. Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA-and E6/E7 mR-NA-based assays of HPV DNA positive women with abnormal Pap smears. J Virol Methods. 2013;222–8.
16.
Moscicki A, Ma Y, Wibbelsman C, Darragh T, Powers A, Farhat S, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;1373–80.
17.
Bulkmans N, Berkhof J, Rozendaal L, Van Kemenade F, Boeke A, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;1764Y – 17672.
18.
Clavel C, Masure M, Bory J, Putaud I, Mangeonjean C, Lorenzato M, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001;1616–23.
19.
Von Karsa L, Arbyn M, Vuyst D, Dillner H, Dillner J, Franceschi L, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015;22–31.
20.
Saslow D, Solomon D, Lawson H, Killackey M, Kulasingam S, Cain J, et al. American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis. 2012;175–204.
21.
Iftner T, Becker S, Neis KJ, Castanon A, Iftner A, Holz B, et al. Head-to-head comparison of the RNA-based Aptima human papillomavirus (HPV) assay and the DNAbased Hybrid Capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. J Clin Microbiol. 2015;2509–16.
22.
Heideman D, Hesselink A, Van Kemenade F, Iftner T, Berkhof J, Topal F, et al. The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening. J Clin Microbiol. 2013;3653–7.
23.
Boulet G, Horvath C, Berghmans S, Bogers J. Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiol Biomarkers Prev. 2008;810–7.
24.
Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, et al. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer. 2013;101–8.
25.
Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, et al. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol. 2010;2779–85.
26.
Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol. 2011;2643–50.
27.
Reid J, Wright T, Jr, Stoler M, Cuzick J, Castle P, et al. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study. Am J Clin Pathol. 2015;473–83.
28.
Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. J Clin Virol. 2016;(Suppl 1):49–55.
29.
Rijkaart D, Berkhof J, Rozendaal L, Van Kemenade F, Bulkmans N, Heideman D, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;78–88.
30.
Engesaeter B, Van Diermen Hidle B, Hansen M, Moltu P, Staby K, Borchgrevink-Persen S, et al. Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study. BMC Infect Dis. 2016;698.
31.
Wright T, Stoler M, Behrens C, Sharma A, Zhang G, Wright T. Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;189–97.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
